15.12.2010 • News

Hadasit Bio-Holdings is an Investment Interest for Sanofi-Aventis

French drugmaker Sanofi-Aventis is in talks to invest in Hadasit Bio-Holdings, the Israeli biotech holding company said on Tuesday.

Hadasit said the potential investment would be in its KHAR Medical unit, but that no deal had yet been reached. It noted that it was responding to a report in Israel's Calcalist newspaper.

Hadasit, the technology transfer company of Jerusalem's Hadassah University Hospital, said the deal could be thwarted by the disclosure of the talks in the newspaper.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.